MY137303A - Methods for treating proliferative diseases - Google Patents

Methods for treating proliferative diseases

Info

Publication number
MY137303A
MY137303A MYPI98005809A MYPI9805809A MY137303A MY 137303 A MY137303 A MY 137303A MY PI98005809 A MYPI98005809 A MY PI98005809A MY PI9805809 A MYPI9805809 A MY PI9805809A MY 137303 A MY137303 A MY 137303A
Authority
MY
Malaysia
Prior art keywords
methods
proliferative diseases
treating proliferative
treating
administering
Prior art date
Application number
MYPI98005809A
Other languages
English (en)
Inventor
Walter R Bishop
Joseph J Catino
Ronald J Doll
Ashit Ganguly
Viyyoor Girijavallabhan
Paul Kirschmeier
Ming Liu
Loretta L Nielsen
David L Cutler
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY137303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MY137303A publication Critical patent/MY137303A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI98005809A 1997-12-22 1998-12-21 Methods for treating proliferative diseases MY137303A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
MY137303A true MY137303A (en) 2009-01-30

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98005809A MY137303A (en) 1997-12-22 1998-12-21 Methods for treating proliferative diseases

Country Status (25)

Country Link
EP (1) EP1041985B1 (enExample)
JP (1) JP4502503B2 (enExample)
KR (1) KR100700907B1 (enExample)
CN (1) CN1129431C (enExample)
AR (1) AR017440A1 (enExample)
AT (1) ATE317697T1 (enExample)
AU (1) AU756762B2 (enExample)
BR (1) BR9814419A (enExample)
CA (1) CA2315693C (enExample)
CL (1) CL2007001889A1 (enExample)
CO (1) CO5080764A1 (enExample)
CZ (1) CZ298511B6 (enExample)
DE (1) DE69833509T2 (enExample)
DK (1) DK1041985T3 (enExample)
ES (1) ES2255196T3 (enExample)
HU (1) HUP0102473A3 (enExample)
IL (1) IL136462A0 (enExample)
MY (1) MY137303A (enExample)
NO (1) NO326832B1 (enExample)
NZ (1) NZ504928A (enExample)
PE (1) PE20000042A1 (enExample)
PT (1) PT1041985E (enExample)
SK (1) SK285584B6 (enExample)
TW (1) TW581763B (enExample)
WO (1) WO1999032114A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
DE60016625T2 (de) * 1999-11-09 2005-12-22 Societe De Conseils De Recherches Et D'applications Scientifiques(S.C.R.A.S.) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
WO2001064197A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2001064226A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064196A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
EP1267871A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
JP4969016B2 (ja) * 2001-02-15 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
TW350844B (en) * 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
JP2000507584A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US20020034725A1 (en) * 1996-04-15 2002-03-21 W. Gillies Mckenna Sensitization of cells to radiation and and chemotherapy
CA2251955A1 (en) * 1996-04-18 1997-10-23 Nancy E. Kohl A method of treating cancer
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
CA2282683A1 (en) * 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
CL2007001889A1 (es) 2008-01-11
EP1041985A1 (en) 2000-10-11
DE69833509T2 (de) 2006-10-26
CN1129431C (zh) 2003-12-03
AU756762B2 (en) 2003-01-23
CN1284875A (zh) 2001-02-21
PT1041985E (pt) 2006-07-31
SK8982000A3 (en) 2001-04-09
NO326832B1 (no) 2009-02-23
JP2001526224A (ja) 2001-12-18
AR017440A1 (es) 2001-09-05
NZ504928A (en) 2004-12-24
HUP0102473A3 (en) 2003-07-28
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
CZ20002236A3 (cs) 2001-04-11
ATE317697T1 (de) 2006-03-15
WO1999032114A1 (en) 1999-07-01
IL136462A0 (en) 2001-06-14
KR100700907B1 (ko) 2007-03-29
ES2255196T3 (es) 2006-06-16
CZ298511B6 (cs) 2007-10-24
TW581763B (en) 2004-04-01
HUP0102473A2 (hu) 2002-01-28
CO5080764A1 (es) 2001-09-25
NO20003229L (no) 2000-08-22
DE69833509D1 (de) 2006-04-20
AU1907299A (en) 1999-07-12
CA2315693C (en) 2010-11-30
EP1041985B1 (en) 2006-02-15
PE20000042A1 (es) 2000-02-17
DK1041985T3 (da) 2006-06-19
KR20010033452A (ko) 2001-04-25
JP4502503B2 (ja) 2010-07-14
NO20003229D0 (no) 2000-06-21
SK285584B6 (sk) 2007-04-05

Similar Documents

Publication Publication Date Title
MY137303A (en) Methods for treating proliferative diseases
MY120841A (en) Methods of inducing cancer cell death and tumor regression
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
GR3036188T3 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
BG105108A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
HU9302384D0 (en) 2,4-diamino-quinazoline derivatives and medical preparatives containing them
AU1051495A (en) Device for treating cancer and non-maligant tumors and methods
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
PL340906A1 (en) Adamantane derivatives
AU3400297A (en) Gm-csf administration for the treatment and prevention of recurrence of brain tumors
HU890950D0 (en) Process for decreasing the harmful side-effects of cancer therapy
AU2701195A (en) Methods for treating cancer and other cell proliferative diseases
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
GB9314623D0 (en) Localization and therapy with agents directed against prostate specific antigen in breast cancer
HK1052870A1 (zh) 诱导癌细胞死亡和肿瘤消退的方法
ZA97657B (en) Ligand directed enzyme prodrug therapy.
CA2298820A1 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
AU6969098A (en) 1,2,4-benzotriazine oxides formulations
AU3274597A (en) Remedies and preventives for stomatitis
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas
IL138117A0 (en) 5-imino-13-deoxy anthracycline derivatives, their uses and processes for preparing them
WO1990011078A8 (en) Regional chemotherapy with 4-hydroperoxycyclophosphamide
GB9723824D0 (en) Cytostatic agents
ES2141044A1 (es) Terapia con oxibutinina.
AU4114196A (en) Combination therapy with estriol and vitamin a, c or e for preventing/treating arterial diseases